2019-04-15

Dear Colleagues:

In follow up to Customer Letter 2017-42 dated 2017-10-31, Canadian Blood Services is pleased to provide an update on recombinant factor VIII and IX transition activities, current contracts and future product availability.

Canadian Blood Services appreciates the partnership and collaboration of the provincial and territorial governments, patient, nursing and physician groups, industry partners and individual hemophilia treatment centers during the recent transition activities. Hemophilia patients requiring a product transition have been safely transitioned to an alternate product. In addition to this, the named patient program allows for continued access to certain alternative products thus ensuring individual patient needs and our fiscal responsibilities continued to be met.

As you are aware, our contracts for recombinant factor VII and IX were awarded until 2020-03-31 with extension options. Canadian Blood Services will be exercising one-year contract extension for the Adynovate® (Shire), Kovaltry® (Bayer), Nuwiq® (Octapharma) and Xyntha® (Pfizer) products thereby ensuring a continuation of current access until at least 2021-03-31. Continued access to Bioverativ's products, Eloctate® and Alprolix®, will be in accordance to the access criteria and the named patient program. Criteria for continued Eloctate® access allows for any current immune tolerance induction (ITI) treatment in hemophilia A. Note that patients younger than 12 years of age are now required to transition from Eloctate® to another product. Canadian Blood Services will follow-up with clinics and hospitals impacted by this transition within the next two weeks. In the case of Alprolix®, patients less than 18 years of age will continue to have access until Rebinyn® is approved for this patient group. Canadian Blood Services product order forms will be updated with this information. As always, any exceptions to these criteria can be considered on a case by case basis by contacting csr@blood.ca.

The products carried will allow for continued patient and physician choice while ensuring a sustainable program within the available funding.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.
This customer letter can also be viewed at www.blood.ca in the “Hospitals Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Isra Levy, MB BCh, MSc, FRCPC
Vice President, Medical Affairs and Innovation